Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT
Author:
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Link
http://www.nature.com/articles/bmt2011210.pdf
Reference8 articles.
1. Bolanos-Meade J, Smith BD, Gore SD, McDevitt MA, Luznik L, Fuchs EJ et al. 5-Azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood and Marrow Transplant 2011; 17: 754–758.
2. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderi S et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635–1640.
3. Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G . Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 2007; 31: 257–259.
4. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009; 115: 1899–1905.
5. Guieze R, Jouinot A, Itzykson R, Thepot S, Guillaurne T, Coiteux V et al. Azacytidine (AZA) in relapsed MDS and AML after allogeneic stem cell transplantation (allo-HSCT): results of the French ATU Program. Blood 2010; 116 (ASH 2010 Annual Meeting Abstracts) 1293.
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Myeloid sarcoma: more and less than a distinct entity;Annals of Hematology;2023-06-07
2. Pediatric Myeloid Sarcoma, More than Just a Chloroma: A Review of Clinical Presentations, Significance, and Biology;Cancers;2023-02-24
3. Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma;Scientific Reports;2022-04-26
4. Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors;Therapeutic Advances in Hematology;2022-01
5. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective;International Immunopharmacology;2021-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3